Aimed Bio

0009K0· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

₩24,200+15.24%

2026-08-04

Financials

Valuation Metrics

Aimed Bio's Market Cap is ₩1.6T. Ranked #237 of 2,436 in KR market (top 10%), #54 of 1,649 on KOSDAQ (top 3%), #24 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 10%) by Market Cap.

Investment Metrics(as of 2026-08-04)

Metric	Value	Rank
Size
Market Cap	1.57T KRW	KR#237/2,436 Sec#24/234
Revenue	47.28B KRW	KR#1,817/2,436 Sec#127/234
Net Income	5.02B KRW	KR#1,127/2,436 Sec#76/234
Total Assets	198.97B KRW	KR#1,285/2,436 Sec#97/234
Net Assets	192.57B KRW	KR#949/2,436 Sec#66/234
Value
P/E	311.88x	KR#1,487/2,436 Sec#103/234
P/B	8.13x	KR#2,314/2,436 Sec#201/234
P/S	33.10x	KR#2,355/2,436 Sec#192/234
EV/EBITDA	70.23x	KR#1,418/2,436 Sec#98/234
FCF Yield	1.12%	KR#1,136/2,436 Sec#81/234
Profitability
ROE	2.61%	KR#1,269/2,436 Sec#90/234
ROA	2.52%	KR#1,039/2,436 Sec#86/234
Op. Margin	43.93%	KR#19/2,436 Sec#4/234
Financial Health
Debt Ratio	103.32%	KR#343/2,436 Sec#46/234
FCF	17.51B KRW	KR#552/2,436 Sec#30/234
Cash	106.41B KRW	KR#448/2,436 Sec#23/234
Current Ratio	31.43x	KR#10/2,436 Sec#5/234
Net Debt/EBITDA	-5.12x	KR#136/2,436 Sec#3/234
Performance
1M Return	-4.35%	KR#1,335/2,436 Sec#135/234
From 52W High	-69.83%	KR#2,132/2,436 Sec#192/234
1Y MDD	-75.31%	KR#2,157/2,436 Sec#194/234
Trading
Volume	392,787 shares	KR#329/2,436 Sec#39/234
Foreign Own.	2.49%	KR#1,048/2,436 Sec#102/234
Per Share
EPS	69 KRW	KR#1,415/2,436 Sec#99/234
BPS	2,967 KRW	KR#1,819/2,436 Sec#142/234

Company Info

CEO 허남구

Founded 2018

HQ 서울특별시 송파구, KR

Website www.aimedbio.com

항체-약물 접합체(ADC) 기반 항암제를 개발하여 기술이전 하는 것을 주요 사업으로 영위함. 환자유래세포(PDC)와 환자유래 이종이식모델(PDX) 등 환자유래모델을 활용한 항체 발굴 역량과, 자체 보유한 링커-페이로드 기술을 활용한 최적의 표적과 개발 전략을 도출할 수 있는 경쟁력을 보유함. 다년간의 임상 경험을 바탕으로 미충족 의료 수요를 발굴하고 이를 신약개발 전략에 반영하는 차별성을 가지고 있음. 에임드바이오는 2018년에 설립되었으며 서울특별시 송파구에 본사를 두고 있습니다.